<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448368</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-111</org_study_id>
    <nct_id>NCT02448368</nct_id>
  </id_info>
  <brief_title>RDEA3170 Tablet and Capsule Bioavailability Study</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relative bioavailability of RDEA3170 capsules
      compared with RDEA3170 tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) and Bioavailability (BA) of RDEA3170 capsules compared with RDEA3170 tablets</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); and apparent terminal half-life (t1/2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of High fat meal on the PK of RDEA3170 capsules</measure>
    <time_frame>Day 1, 5, 9, 13, 17</time_frame>
    <description>PK endpoints in terms Cmax; Tmax; AUC; and t1/2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of RDEA3170</measure>
    <time_frame>Day -1, 1, 5, 9, 13, 17</time_frame>
    <description>PD endpoints in terms of Serum urate (sUA) concentration, Urin Uric acid excretion amount, renal clearance of uric acid, and fractional excretion of uric acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in Laboratory, Electrocardiogram and Vital Signs Parameters.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RDEA3170 capsules or tablets 5 mg and 10 mg, 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: RDEA3170, 5 mg, administered in the fasted state. Treatment B: RDEA3170, 5 mg, administered in the fed state. Treatment C: RDEA3170, 10 mg, administered in the fasted state. Treatment D: RDEA3170, 10 mg, administered in the fed state. Treatment E: RDEA3170, 2.5 mg, administered as 10 mg in the fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170,10 mg</intervention_name>
    <description>Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.</description>
    <arm_group_label>RDEA3170 capsules or tablets 5 mg and 10 mg, 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170, 2.5 mg</intervention_name>
    <description>Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.</description>
    <arm_group_label>RDEA3170 capsules or tablets 5 mg and 10 mg, 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170, 5 mg</intervention_name>
    <description>Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.</description>
    <arm_group_label>RDEA3170 capsules or tablets 5 mg and 10 mg, 2.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to understand the study procedures and the risks involved, and is
             willing to provide written informed consent before the first study-related activity.

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40
             kg/m2.

          -  Subject has a Screening serum urate level of 4 to 7 mg/dL.

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has undergone major surgery within 3 months prior to Screening.

          -  Subject donated blood or experienced significant blood loss within 12 weeks prior to
             Day 1 or gave a plasma donation within 4 weeks prior to Day 1.

          -  Subject has clinically unacceptable physical examination, per the Investigator's
             judgment.

          -  Subject has clinically relevant abnormalities in blood pressure, heart rate, or body
             temperature, per the Investigator's judgment.

          -  Subject has Screening clinical safety laboratory parameters (serum chemistry [other
             than serum creatinine and serum urate], hematology, coagulation or urinalysis) that
             are outside the normal limits and are considered clinically significant by the
             Investigator.

          -  Subject has a serum creatinine value above the upper limit of normal at the Screening
             visit.

          -  Subject has clinically relevant abnormalities in 12-lead electrocardiogram, per the
             Investigator's judgment.

          -  Subject has a history of cardiac abnormalities

          -  Subject cannot swallow multiple tablets or capsules.

          -  Subject has received any strong or moderate enzyme-inducing drug or product within 2
             months prior to Day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>June 12, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>June 13, 2017</submitted>
    <returned>October 31, 2017</returned>
    <submitted>November 17, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

